Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Nanobiotix S.A. is a biotechnology company focused on developing innovative cancer therapies using its proprietary nanotechnology platform. The company is primarily engaged in the development of NBTXR3, a product designed to enhance the efficacy of radiotherapy in solid tumors, with ongoing clinical trials in Europe and the U.S.
Nanobiotix's business model is centered around developing and commercializing its lead product, NBTXR3, which aims to improve cancer treatment outcomes. The company has a competitive advantage through its unique nanotechnology that enhances the effectiveness of existing therapies, potentially allowing for higher pricing power once commercialized.
Clinical trial results for NBTXR3, particularly in pivotal studies
Regulatory approvals from the FDA or EMA for NBTXR3
Partnership announcements with larger pharmaceutical companies
Market sentiment around biotechnology sector performance
Regulatory changes impacting drug approval processes
Technological disruption from competing cancer therapies
Emergence of alternative cancer treatments that could overshadow NBTXR3
Increased competition from established biotech firms with more resources
High cash burn rate due to R&D expenditures
Potential dilution of shares if additional funding is required
low - The biotechnology sector is generally less sensitive to economic cycles, as demand for healthcare and innovative treatments remains relatively stable.
Moderate - Rising interest rates could increase the cost of capital for R&D funding, impacting the company's ability to finance its operations and clinical trials.
minimal - The company has a negative debt/equity ratio, indicating no reliance on debt financing.
growth - Investors looking for high-risk, high-reward opportunities in the biotech sector.
high - The stock has exhibited significant volatility, particularly with recent returns of 572.1% over the past year.
